BIOMAT Database Logo BIOMAT Database Logo

Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. 2004

S Yeung, and W K Tsang, and K L Tong, and S H Wong, and W Lee, and H L Tang, and H W H Chan, and A Y W Chan
Department of Medicine, Tseung Kwan O Hospital, Kowloon, Hong Kong, China. yeungsj@yahoo.com

Both tacrolimus and mycophenolate mofetil (MMF) are potent immunosuppressive agents used in combination for prevention of acute rejection in renal transplantation. We studied the efficacy and safety of tacrolimus/MMF-based primary immunosuppression as well as their pharmacokinetics (PK) in Chinese renal transplant recipients. Oral tacrolimus was initiated at about 0.2 mg/kg/d, dose which was adjusted to achieve target trough levels of 10 to 20 ng/mL at 3 months and 5 to 10 ng/mL thereafter. The patients also received MMF (0.5 g bid) and prednisolone. PK profiles were studied at 1 week, and 1, 3, and 6 months posttransplant. Blood samples were taken at 0 (predose), 20, 40, 60, 75, and 90 minutes and 2, 4, 6, 8, 10, and 12 hours postdose for each profile. Plasma MPA and whole blood tacrolimus levels were determined by HPLC and EMIT methods respectively. Eight patients were studied with mean follow-up of 16.1 +/- 2.4 months. One patient (12.5%) experienced a borderline acute rejection episode. Both 1-year graft and patient survival rates were 100%. Posttransplant diabetes, diarrhea, and hand tremor occurred in 12.5%, 12.5%, and 37.5%, respectively. No patient had an opportunistic infection. Tacrolimus trough concentrations showed a fair correlation with AUC(0-12h) (R(2) = 0.587). Mean MPA AUC values at 1, 3, and 6 months were 40.5 +/- 9.4, 44.4 +/- 17.3, and 57.2 +/- 20.7 mug*h/mL, respectively (P = .0486, n = 7). In conclusion, primary immunosuppression with tacrolimus, low-dose MMF (0.5 g bid), and prednisolone is effective and safe with adequate systemic MPA exposure in renal transplant recipients.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D002681 China A country spanning from central Asia to the Pacific Ocean. Inner Mongolia,Manchuria,People's Republic of China,Sinkiang,Mainland China
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S Yeung, and W K Tsang, and K L Tong, and S H Wong, and W Lee, and H L Tang, and H W H Chan, and A Y W Chan
Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients.
January 1998, Transplantation,
S Yeung, and W K Tsang, and K L Tong, and S H Wong, and W Lee, and H L Tang, and H W H Chan, and A Y W Chan
Immunosuppression with generic tacrolimus and mycophenolate mofetil in renal transplant recipients: preliminary report in Chile.
April 2008, Transplantation proceedings,
S Yeung, and W K Tsang, and K L Tong, and S H Wong, and W Lee, and H L Tang, and H W H Chan, and A Y W Chan
Primary immunosuppression with tacrolimus and mycophenolate mofetil versus cyclosporine and azathioprine in heart transplant recipients.
June 2002, Transplantation proceedings,
S Yeung, and W K Tsang, and K L Tong, and S H Wong, and W Lee, and H L Tang, and H W H Chan, and A Y W Chan
Tacrolimus plus low-dose mycophenolate mofetil in renal transplant recipients: better 2-year graft and patient survival than with a higher mycophenolate mofetil dose.
September 2005, Transplantation proceedings,
S Yeung, and W K Tsang, and K L Tong, and S H Wong, and W Lee, and H L Tang, and H W H Chan, and A Y W Chan
Mycophenolate mofetil immunosuppression in high-risk renal transplant recipients.
December 1998, Transplantation proceedings,
S Yeung, and W K Tsang, and K L Tong, and S H Wong, and W Lee, and H L Tang, and H W H Chan, and A Y W Chan
Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients.
July 2001, Transplantation,
S Yeung, and W K Tsang, and K L Tong, and S H Wong, and W Lee, and H L Tang, and H W H Chan, and A Y W Chan
Daclizumab induction for primary kidney transplant recipients using tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression.
January 2001, Transplantation proceedings,
S Yeung, and W K Tsang, and K L Tong, and S H Wong, and W Lee, and H L Tang, and H W H Chan, and A Y W Chan
Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
April 2002, Transplantation,
S Yeung, and W K Tsang, and K L Tong, and S H Wong, and W Lee, and H L Tang, and H W H Chan, and A Y W Chan
Individualization of mycophenolate mofetil dose in renal transplant recipients.
March 2006, Expert opinion on pharmacotherapy,
S Yeung, and W K Tsang, and K L Tong, and S H Wong, and W Lee, and H L Tang, and H W H Chan, and A Y W Chan
Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients.
June 1998, Transplantation proceedings,
Copied contents to your clipboard!